Related Experiment Video

Updated: Apr 21, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.1K

The future of research in neuropathy

Takayuki Itoh1, David Pleasure2

  • 1Institute for Pediatric Regenerative Medicine, University of California, Davis, School of Medicine, Sacramento.

JAMA Neurology
|November 4, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Three-dimensional Imaging of Nociceptive Intraepidermal Nerve Fibers in Human Skin Biopsies
11:22

Three-dimensional Imaging of Nociceptive Intraepidermal Nerve Fibers in Human Skin Biopsies

Published on: April 29, 2013

12.7K
Novel Surgical Rodent Model for Studying Neuroma Pain Treatment Options using Targeted Muscle Reinnervation Through the Saphenous Nerve
07:00

Novel Surgical Rodent Model for Studying Neuroma Pain Treatment Options using Targeted Muscle Reinnervation Through the Saphenous Nerve

Published on: November 14, 2025

263

Related Experiment Videos

Last Updated: Apr 21, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.1K
Three-dimensional Imaging of Nociceptive Intraepidermal Nerve Fibers in Human Skin Biopsies
11:22

Three-dimensional Imaging of Nociceptive Intraepidermal Nerve Fibers in Human Skin Biopsies

Published on: April 29, 2013

12.7K
Novel Surgical Rodent Model for Studying Neuroma Pain Treatment Options using Targeted Muscle Reinnervation Through the Saphenous Nerve
07:00

Novel Surgical Rodent Model for Studying Neuroma Pain Treatment Options using Targeted Muscle Reinnervation Through the Saphenous Nerve

Published on: November 14, 2025

263

Related Concept Videos

Diabetic Neuropathy01:22

Diabetic Neuropathy

16
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
16

Articles linked to this work by shared authors, journal, and citation graph.

HiRegEx: Interactive Visual Query and Exploration of Multivariate Hierarchical Data.

IEEE transactions on visualization and computer graphics·2024

Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.

Annals of clinical and translational neurology·2024

Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.

Glia·2023

Therapeutic Potentials of Poly (ADP-Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept Revisiting.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2021

Reduction in CD11c+ microglia correlates with clinical progression in chronic experimental autoimmune demyelination.

Neurobiology of disease·2021

Ablating the Transporter Sodium-Dependent Dicarboxylate Transporter 3 Prevents Leukodystrophy in Canavan Disease Mice.

Annals of neurology·2021

Lifelong De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors.

JAMA neurology·2026

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

JAMA neurology·2026

Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.

JAMA neurology·2026

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

JAMA neurology·2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

JAMA neurology·2026

Plasma Biomarkers for Neocortical Tau Burden.

JAMA neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us